Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition
Abstract Background Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-01-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13195-020-00751-x |
| _version_ | 1819320525205274624 |
|---|---|
| author | Jong-Chan Park Keum Sim Jung Jiyeong Kim Ji Sung Jang Sunghoon Kwon Min Soo Byun Dahyun Yi Gihwan Byeon Gijung Jung Yu Kyeong Kim Dong Young Lee Sun-Ho Han Inhee Mook-Jung |
| author_facet | Jong-Chan Park Keum Sim Jung Jiyeong Kim Ji Sung Jang Sunghoon Kwon Min Soo Byun Dahyun Yi Gihwan Byeon Gijung Jung Yu Kyeong Kim Dong Young Lee Sun-Ho Han Inhee Mook-Jung |
| author_sort | Jong-Chan Park |
| collection | DOAJ |
| description | Abstract Background Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the effectiveness of such strategies remains controversial. Methods We developed a new multiplex kit, the QPLEX™ Alz plus assay kit, which uses proteomics-based blood biomarkers to prescreen for cerebral amyloid deposition. A total of 300 participants who underwent Pittsburgh compound B (PiB)-positron emission tomography (PET) which allows imaging of cerebral amyloid deposition were included in this study. We compared the levels of QPLEX™ biomarkers between patients who were classified as PiB-negative or PiB-positive, regardless of their cognitive function. Logistic regression analysis followed by receiver operating characteristic (ROC) curve analysis was performed. The kit accuracy was tested using a randomized sample selection method. Results The results obtained using our assay kit reached 89.1% area under curve (AUC) with 80.0% sensitivity and 83.0% specificity. Further validation of the QPLEX™ Alz plus assay kit using a randomized sample selection method showed an average accuracy of 81.5%. Conclusions Our QPLEX™ Alz plus assay kit provides preliminary evidence that it can be used as blood marker to predict cerebral amyloid deposition but independent validation is needed. |
| first_indexed | 2024-12-24T11:20:58Z |
| format | Article |
| id | doaj.art-861d8581c821400a9be71d6ffd8879c9 |
| institution | Directory Open Access Journal |
| issn | 1758-9193 |
| language | English |
| last_indexed | 2024-12-24T11:20:58Z |
| publishDate | 2021-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj.art-861d8581c821400a9be71d6ffd8879c92022-12-21T16:58:14ZengBMCAlzheimer’s Research & Therapy1758-91932021-01-0113111010.1186/s13195-020-00751-xPerformance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid depositionJong-Chan Park0Keum Sim Jung1Jiyeong Kim2Ji Sung Jang3Sunghoon Kwon4Min Soo Byun5Dahyun Yi6Gihwan Byeon7Gijung Jung8Yu Kyeong Kim9Dong Young Lee10Sun-Ho Han11Inhee Mook-Jung12Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National UniversityQuantaMatrix Inc.QuantaMatrix Inc.QuantaMatrix Inc.QuantaMatrix Inc.Department of Neuropsychiatry, Seoul National University Bundang HospitalDepartment of Neuropsychiatry, Seoul National University HospitalDepartment of Neuropsychiatry, Seoul National University HospitalDepartment of Neuropsychiatry, Seoul National University HospitalDepartment of Nuclear Medicine, SMG-SNU Boramae Medical CenterDepartment of Neuropsychiatry, Seoul National University HospitalDepartment of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National UniversityDepartment of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National UniversityAbstract Background Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the effectiveness of such strategies remains controversial. Methods We developed a new multiplex kit, the QPLEX™ Alz plus assay kit, which uses proteomics-based blood biomarkers to prescreen for cerebral amyloid deposition. A total of 300 participants who underwent Pittsburgh compound B (PiB)-positron emission tomography (PET) which allows imaging of cerebral amyloid deposition were included in this study. We compared the levels of QPLEX™ biomarkers between patients who were classified as PiB-negative or PiB-positive, regardless of their cognitive function. Logistic regression analysis followed by receiver operating characteristic (ROC) curve analysis was performed. The kit accuracy was tested using a randomized sample selection method. Results The results obtained using our assay kit reached 89.1% area under curve (AUC) with 80.0% sensitivity and 83.0% specificity. Further validation of the QPLEX™ Alz plus assay kit using a randomized sample selection method showed an average accuracy of 81.5%. Conclusions Our QPLEX™ Alz plus assay kit provides preliminary evidence that it can be used as blood marker to predict cerebral amyloid deposition but independent validation is needed.https://doi.org/10.1186/s13195-020-00751-xAlzheimer’s diseasePittsburgh compound BCerebral amyloid depositionBlood-based biomarkerQPLEX™ Alz plus assay |
| spellingShingle | Jong-Chan Park Keum Sim Jung Jiyeong Kim Ji Sung Jang Sunghoon Kwon Min Soo Byun Dahyun Yi Gihwan Byeon Gijung Jung Yu Kyeong Kim Dong Young Lee Sun-Ho Han Inhee Mook-Jung Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition Alzheimer’s Research & Therapy Alzheimer’s disease Pittsburgh compound B Cerebral amyloid deposition Blood-based biomarker QPLEX™ Alz plus assay |
| title | Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition |
| title_full | Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition |
| title_fullStr | Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition |
| title_full_unstemmed | Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition |
| title_short | Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition |
| title_sort | performance of the qplex™ alz plus assay a novel multiplex kit for screening cerebral amyloid deposition |
| topic | Alzheimer’s disease Pittsburgh compound B Cerebral amyloid deposition Blood-based biomarker QPLEX™ Alz plus assay |
| url | https://doi.org/10.1186/s13195-020-00751-x |
| work_keys_str_mv | AT jongchanpark performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT keumsimjung performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT jiyeongkim performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT jisungjang performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT sunghoonkwon performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT minsoobyun performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT dahyunyi performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT gihwanbyeon performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT gijungjung performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT yukyeongkim performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT dongyounglee performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT sunhohan performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition AT inheemookjung performanceoftheqplexalzplusassayanovelmultiplexkitforscreeningcerebralamyloiddeposition |